press releases

Investors may listen to the call on March 26, 2020 at 8:30 am ET by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 2666529.
Mar 26, 2020 at 8:30 AM EDT
Date Title Teaser
Date Title  
03/31/20
BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma PRINCETON, NJ . & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc
 
03/26/20
- Company to hold investor conference call today, March 26, 2020 at 8:30 am ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to ensure the safety of its
 
02/18/20
- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β 0 /β 0 genotype in Europe achieved in 2019; Germany launch underway – - Announced positive
 
02/05/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference , Wednesday, February 26 , at 2:30 p.m.
 
01/13/20
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patients
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.